$WENA News
Last published 2y ago
- 2y agoWENAKLTOANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.GlobeNewswireNEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The Board of ANEW MEDICAL, INC. (NASDAQ:WENA), today announced a name and ticker symbol change to Klotho Neurosciences, Inc. (NASDAQ:KLTO), and has launched a new website,
- 2y agoWENAHealthy Longevity is One of Key Development Goals of ANEW's Novel Gene TherapyGlobeNewswireNEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ:WENA), a U.S. biotechnology company, announced that it has two distinct goals for its pioneering cell and gene therapy development. One is to
- 2y agoWENAANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial FlexibilityGlobeNewswireNEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ:WENA), a leading U.S. biotechnology company pioneering cell and gene-based treatments for aging and age-related diseases, announces the successful
- 2y agoWENAANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke ("TTS")GlobeNewswireNEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or the "Company") (NASDAQ:WENA) announced the signing of an exclusive worldwide license agreement with Transfertech Sherbrooke ("TTS") regarding
- 2y agoWENAANEW MEDICAL, INC. Appoints New CFOGlobeNewswireNEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (NASDAQ:WENA) a U.S.-based biotechnology company focused on developing cell and gene-based treatments for aging, and age-related
- 2y agoWENAANEW MEDICAL, INC. Strengthens Intellectual Property Protection with U.S. Patent Issuance for Its Secreted RNA Splice Variant of the Human Klotho Gene Used for the Treatment of Neurodegenerative and Age-Related DiseasesGlobeNewswireNEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (NASDAQ:WENA) a U.S. -based biotechnology company focused on developing cell and gene-based treatments for aging, and age-related
- 2y agoWENAANEW MEDICAL, INC. Pursues Neurological Approach to Treating Weight Loss and Eating Disorders through Melanocortin Receptor Binding PeptidesGlobeNewswireMelanocortin receptors on neurons in the brain control feeding and weight lossPatented peptide molecules delivered orally as a pill can control feeding disorders and weight loss NEW YORK, Aug. 09, 2024 (GLOBE
- 2y agoWENAANEW MEDICAL, INC. Announces Patents Issued in Major Asian Markets for use of Genetic Therapy in the Treatment of Alzheimer's Disease and ALSGlobeNewswirePatents issued in mainland China protect the Company's novel secreted Klotho protein and Its gene delivery systemRecent Patents issued in Hong Kong and Shanghai support protection to develop treatments for Alzheimer's
- 2y agoWENAANEW MEDICAL to Advance Patented Klotho Gene Therapy for Neurodegenerative Disorder TreatmentsGlobeNewswireGenomics data suggests having an active Klotho gene sequence may help people live longer, healthier lives The Company was granted patents in Europe, China, and Hong Kong and awaits issuance of patents in the U.S. and
- 2y agoWENAANEW MEDICAL Forms Strategic Partnership with Japan's Okinawa Research Center for Longevity Science (ORCLS) to Study Klotho GeneGlobeNewswireCollaboration focuses on research and development of ANEW's patented Klotho gene therapy in enhancing longevity and reducing age-related diseases ANEW's mission is to deliver transformative protein, cell, and gene
- 2y agoWENAANEW MEDICAL, INC. Secures Key Patent in Europe for Human Klotho Gene RNA Slice Variant and ProteinGlobeNewswireANEW to explore therapeutics and specialty diagnostics utilizing the s-KL protein and will pursue other medical product development and commercial opportunities of interestExclusive, worldwide intellectual property